Cytori Therapeutics Inc (NASDAQ:CYTX) major shareholder Bank Sa Swissquote sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $0.38, for a total transaction of $38,000.00. Following the completion of the sale, the insider now owns 5,496,655 shares of the company’s stock, valued at approximately $2,088,728.90. The transaction was disclosed in a document filed with the SEC, which is available at this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Bank Sa Swissquote also recently made the following trade(s):
- On Thursday, January 11th, Bank Sa Swissquote sold 72,630 shares of Cytori Therapeutics stock. The shares were sold at an average price of $0.34, for a total transaction of $24,694.20.
Shares of Cytori Therapeutics Inc (NASDAQ:CYTX) traded down $0.01 on Friday, reaching $0.39. 2,013,101 shares of the company’s stock were exchanged, compared to its average volume of 2,360,000. The company has a market capitalization of $13.20, a price-to-earnings ratio of -0.43 and a beta of 3.56. Cytori Therapeutics Inc has a 1 year low of $0.22 and a 1 year high of $2.13.
Cytori Therapeutics (NASDAQ:CYTX) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.14) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.02. The business had revenue of $1.77 million for the quarter, compared to analyst estimates of $2.04 million. Cytori Therapeutics had a negative net margin of 367.33% and a negative return on equity of 228.21%. During the same quarter in the previous year, the firm posted ($0.26) earnings per share. analysts forecast that Cytori Therapeutics Inc will post -0.62 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Perkins Capital Management Inc. increased its holdings in shares of Cytori Therapeutics by 134.0% in the fourth quarter. Perkins Capital Management Inc. now owns 2,136,041 shares of the biotechnology company’s stock valued at $644,000 after purchasing an additional 1,223,046 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Cytori Therapeutics by 81.9% in the second quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock valued at $674,000 after purchasing an additional 275,653 shares during the last quarter. Finally, Sabby Management LLC increased its holdings in shares of Cytori Therapeutics by 28.0% in the second quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock valued at $1,789,000 after purchasing an additional 355,504 shares during the last quarter. Institutional investors and hedge funds own 7.34% of the company’s stock.
Several equities research analysts have recently commented on the stock. Maxim Group set a $5.00 price target on shares of Cytori Therapeutics and gave the stock a “buy” rating in a research report on Thursday, October 19th. Zacks Investment Research cut shares of Cytori Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. ValuEngine raised shares of Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday. Finally, B. Riley reissued a “hold” rating on shares of Cytori Therapeutics in a research note on Tuesday, November 7th.
COPYRIGHT VIOLATION WARNING: This story was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/03/cytori-therapeutics-inc-cytx-major-shareholder-sells-38000-00-in-stock.html.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.